[go: up one dir, main page]

HUP9800613A2 - Humán Fas-antigén elleni humanizált antitest - Google Patents

Humán Fas-antigén elleni humanizált antitest

Info

Publication number
HUP9800613A2
HUP9800613A2 HU9800613A HUP9800613A HUP9800613A2 HU P9800613 A2 HUP9800613 A2 HU P9800613A2 HU 9800613 A HU9800613 A HU 9800613A HU P9800613 A HUP9800613 A HU P9800613A HU P9800613 A2 HUP9800613 A2 HU P9800613A2
Authority
HU
Hungary
Prior art keywords
subject
antibodies
antigene
humanized antibody
antibody against
Prior art date
Application number
HU9800613A
Other languages
English (en)
Inventor
Hideyuki Haruyama
Kaori Nakahara
Nobufusa Serizawa
Tohru Takahashi
Shin Yonehara
Original Assignee
Sankyo Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company Limited filed Critical Sankyo Company Limited
Publication of HU9800613D0 publication Critical patent/HU9800613D0/hu
Publication of HUP9800613A2 publication Critical patent/HUP9800613A2/hu
Publication of HUP9800613A3 publication Critical patent/HUP9800613A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány tárgya hűmán Fas-antigén elleni hűmanizált antitestek,valamint az ilyen antitesteket kódőló DNS-ek képezik. A találmánytárgyát képezik tővábbá a találmány szerinti antitesteket tartalmazógyógyászati készítmények, amelyek elsősőrban aűtőimműn betegségek ésreűmatikűs betegségek kezelésére alkalmazhatók. A találmány szerintikészítmények adőtt esetben sejtszapőrődást gátló anyagőt istartalmaznak. A találmány tárgyát képezik a találmány szerinti hűmanizált antitestekelőállítási eljárásai is, tővábbá a hűmanizált antitesteket kódőlóRNS-ek, a találmány szerinti DNS-eket tartalmazó vektőrők, a találmányszerinti vektőrőkkal transzfőrmált gazdasejtek, valamint a találmányszerinti antitestek alklamazása aűtőimműn betegség kezelésére alkalmasgyógyszer előállítására. ŕ
HU9800613A 1997-03-21 1998-03-20 Humanized antibody against human fas-antigene HUP9800613A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6793897 1997-03-21

Publications (3)

Publication Number Publication Date
HU9800613D0 HU9800613D0 (en) 1998-05-28
HUP9800613A2 true HUP9800613A2 (hu) 1999-02-01
HUP9800613A3 HUP9800613A3 (en) 2001-04-28

Family

ID=13359383

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9800613A HUP9800613A3 (en) 1997-03-21 1998-03-20 Humanized antibody against human fas-antigene

Country Status (15)

Country Link
EP (1) EP0866131A3 (hu)
KR (1) KR19980080514A (hu)
AR (1) AR012148A1 (hu)
AU (1) AU736287B2 (hu)
BR (1) BR9800937A (hu)
CA (1) CA2232828A1 (hu)
CZ (1) CZ85898A3 (hu)
HU (1) HUP9800613A3 (hu)
ID (1) ID20065A (hu)
IL (1) IL123756A0 (hu)
NO (1) NO981272L (hu)
NZ (1) NZ330004A (hu)
PL (1) PL325457A1 (hu)
TR (1) TR199800517A3 (hu)
ZA (1) ZA982371B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
WO1999065935A2 (en) * 1998-06-18 1999-12-23 Karolinska Innovations Ab Fas peptides and antibodies for modulating apoptosis
AU757961B2 (en) * 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
MXPA01006998A (es) * 1999-01-11 2002-05-06 Leadd Bv Uso de agentes inductores de apoptosis en el tratamiento de enfermedades (auto) inmunitarias.
AU2004233486B2 (en) * 1999-01-11 2007-09-13 Leadd B.V. Use of apoptosis inducing agents in the treatment of (auto)immune diseases
NZ515598A (en) 1999-05-24 2004-05-28 Sankyo Co Synergistic medicinal compositions containing anti-Fas antibody and a compound having a folate antagonistic activity or a dihydrofolate reductase inhibiting activity
CN1646161A (zh) 2002-02-21 2005-07-27 杜克大学 自身免疫疾病的药剂和治疗方法
EP1506237A1 (en) * 2002-05-17 2005-02-16 Fusion Antibodies Limited Treatment of cancer by the use of anti fas antibody
GB0306618D0 (en) * 2003-03-22 2003-04-30 Univ Newcastle Antibody
EP2540741A1 (en) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US8030026B2 (en) * 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
WO2017083525A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
CA2174132A1 (en) * 1993-10-14 1995-04-20 Immunex Corporation Fas antagonists and uses thereof
CA2158822C (en) * 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
AU724579B2 (en) * 1996-04-01 2000-09-28 Sankyo Company Limited Anti-Fas recombinant antibodies and DNA therefor

Also Published As

Publication number Publication date
NO981272L (no) 1998-09-22
HUP9800613A3 (en) 2001-04-28
EP0866131A3 (en) 1999-12-15
AR012148A1 (es) 2000-09-27
AU5937598A (en) 1998-10-15
CA2232828A1 (en) 1998-09-21
IL123756A0 (en) 1998-10-30
TR199800517A2 (xx) 1998-10-21
TR199800517A3 (tr) 1998-10-21
ID20065A (id) 1998-09-24
NZ330004A (en) 1998-10-28
KR19980080514A (ko) 1998-11-25
HU9800613D0 (en) 1998-05-28
EP0866131A2 (en) 1998-09-23
NO981272D0 (no) 1998-03-20
PL325457A1 (en) 1998-09-28
ZA982371B (en) 1998-09-28
CZ85898A3 (cs) 1998-10-14
BR9800937A (pt) 2000-01-11
AU736287B2 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
RU2220980C2 (ru) Химерное антитело, которое связывается с cd40 человека (варианты), молекула нуклеиновой кислоты (варианты), вектор экспрессии (варианты), гуманизированное антитело (варианты), фармацевтическая композиция для лечения заболевания, опосредованного т-клетками (варианты), способ лечения больного от заболевания, опосредованного т-клетками (варианты)
Kornbluth et al. Association of the polyomavirus middle-T antigen with c-yes protein
Habets et al. Antibodies against distinct nuclear matrix proteins are characteristic for mixed connective tissue disease
Goldstein History of the discovery of the thymosins
RU2317998C2 (ru) Антитела человека, обладающие активностью связывания c mn и нейтрализации клеточной адгезии
HUP0104717A2 (hu) Készítmények és eljárások petefészekrák terápiájára és diagnózisára
Laman et al. Cutaneous manifestations of lupus erythematosus
HUP9800613A2 (hu) Humán Fas-antigén elleni humanizált antitest
IL145535A0 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
WO1998021334A3 (en) Antibody mg1 recognizing a small subset of human hematopoietic cells
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
EE05212B1 (et) Polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on m?eldud kasvajaraku raviks, mis ekspresseerib APRIL-i
DE68928069D1 (de) Anti-T-Zell Rezeptordeterminanten zur Behandlung von Autoimmunkrankheiten
BR0308953A (pt) composições, proteìna, polinucleotìdeo, método de geração de uma resposta imune, método de detecção, composição farmacêutica, anticorpo ou seu fragmento, animal transgênico, hibridoma, método de fornecimento de um agente citotóxico ou agente de diagnóstico e método de inibição do crescimento de células cancerosas
ATE132197T1 (de) Monoklonale antikörper
IL138424A (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
EA200300815A1 (ru) Способ клеточной терапии для лечения опухолей
ATE173740T1 (de) Antikoerper mit geaenderter zielrichtung
HUP9901908A2 (hu) p16 Expressziós konstrukciók és alkalmazásuk rákterápiában
Shetty et al. Anti‐Cytokine Active Immunotherapy Based on Supramolecular Peptides for Alleviating IL‐1β‐Mediated Inflammation
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
ES2046173T3 (es) Lineas celulares de hibridoma y sus anticuerpos monoclonales con respecto al factor estimulador de colonias de granulocitos pluripotentes humanos.
HUP9700676A2 (hu) Rekombináns anti-Fas antitestek és az ezeket kódoló DNS
Roos et al. Determination of the epitope of an inhibitory antibody to proliferating cell nuclear antigen
ATE164311T1 (de) Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten